CSPC PHARMA (01093.HK): JMT206 Phase Ib Obesity Trial Starts in China
- JMT206 Injection is registered as a Class 1 therapeutic biological product and is a recombinant fully human anti-ActR-IIA and anti-ActR-IIB monoclonal antibody that blocks the activation of both signalling pathways to promote muscle mass gain and reduce body weight.
- In November 2025, the Group obtained the NMPA's Notice of Approval for Clinical Trial of Drug for the overweight or obesity indication and initiated the Phase I trial, whose data preliminarily verified safety, pharmacokinetics and pharmacodynamics in healthy participants.
- The Phase Ib trial is a randomised, double-blind, placebo parallel-controlled study evaluating multiple subcutaneous injections of the Product, as monotherapy or combined with semaglutide injection, in obese participants.
NewTimeSpace News: On 29 September 2026, CSPC Pharmaceutical Group Limited (stock code: 01093.HK) announced that the Phase Ib clinical trial (JMT206–003) of JMT206 Injection, developed by the Group for weight management in adult patients with overweight or obesity, has been officially initiated at the first study centre in China.
The Product is registered as a Class 1 therapeutic biological product and is a recombinant fully human anti-activin receptor type IIA (ActR-IIA) and type IIB (ActR-IIB) monoclonal antibody. It specifically binds to ActR-IIA and ActR-IIB on the surface of target cell membranes, blocking the activation of both signalling pathways, thereby promoting an increase in muscle mass and reducing body weight. Pre-clinical studies demonstrated muscle-building and fat-reducing effects alongside a safety and tolerability profile.
In November 2025, the Group obtained the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration for the overweight or obesity indication, and initiated the Phase I clinical trial following the approval. Phase I data preliminarily verified the safety, pharmacokinetic and pharmacodynamic profiles of the Product in healthy participants.
The Phase Ib trial is a randomised, double-blind, placebo parallel-controlled trial evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of multiple subcutaneous injections of the Product, as monotherapy or in combination with semaglutide injection, in obese participants. Recruitment and screening of participants are being actively advanced.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC PHARMA (01093.HK): SYS6077 injection wins clinical trial nod
- CSPC PHARMA (01093.HK): Phase III Trial of Becotatug (JMT101) plus Osimertinib Meets Primary Endpoint, Significantly Extending PFS
- CSPC PHARMA (01093.HK): HB1801 Phase III Trial Starts in China
- CSPC PHARMA (01093.HK): Phase II Trial of SYH2069 Injection for Adult Type 2 Diabetes Commences at First Site in China
- CSPC PHARMA (01093.HK): SYS6010 Included in China's Breakthrough Therapy Designation List for Driver-Gene-Negative Non-Squamous NSCLC
